All In Biotech

Drug Trial Radar · NCT06702566

The Effect of Serum Ferritin in irAE

The Significance of Serum Ferritin in the Diagnosis, Differential Diagnosis, and Prognosis of Immune-related Adverse Event (irAE)

Last checked: Nov 19, 2026Latest source record: Nov 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,500

Planned (sponsor's estimate)

Start

Jul 4, 2024

Primary completion

Jul 16, 2026

Study completion Jul 1, 2027

Sponsor

Lead sponsor
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective clinical study to clarify serum ferritin as a biomarker for the diagnosis, differential diagnosis and prognosis of immune-related adverse event(irAE).

Conditions

  • Immune-related Adverse Event
  • Malignant Solid Tumors
  • Acute Leukemia
  • Serum Ferritin

Interventions

  • PD-1 and PD-L1 inhibitorDrug

    PD-1 inhibitor includes pembrolizumab,Nivolumab,Sintilimab,tislelizumab,Triplimab,Camrelizumab, Serplulimab. PD-L1 inhibitor includes durvalumab,Atezolizumab,Adebrelimab,Envafolimab.

  • Targeted drugsDrug

    Targeted drugs includes EGFR-TKIs,ALK-TKIs,Multitargeted Tyrosine Kinase Inhibitors, VEGF antibody, EGFR antibody, antibody-drug conjugates drugs

  • chemotherapy drugsDrug

    Chemotherapy drugs are determined based on the investigator's decision.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. calculated cut-off value for serum ferritin in the diagnosis of irAETime frame: 1 year
  2. Determining the sensitivity and specificity of serum ferritin in the diagnosis of irAETime frame: 1 year
  3. Determining baseline level of serum ferritin predicts irAE occurrenceTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.